• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Harrow, Inc. - Common Stock (NQ:HROW)

    42.13 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 20, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Harrow, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
    From Harrow, Inc.
    Via Business Wire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
    From Pomerantz LLP
    Via GlobeNewswire
    Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
    From Harrow, Inc.
    Via Business Wire
    Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
    From Harrow, Inc.
    Via Business Wire
    Harrow to Present at Two Investor Conferences in May
    From Harrow, Inc.
    Via Business Wire
    Harrow Announces First-Quarter 2025 Financial Results
    From Harrow, Inc.
    Via Business Wire
    Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025
    From Harrow, Inc.
    Via Business Wire
    Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
    From Harrow, Inc.
    Via Business Wire
    Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
    From Harrow, Inc.
    Via Business Wire
    Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
    From Harrow, Inc.
    Via Business Wire
    Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
    From Harrow, Inc.
    Via Business Wire
    Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
    From Harrow, Inc.
    Via Business Wire
    Harrow Launches VEVYE® Access for All
    From Harrow, Inc.
    Via Business Wire
    Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
    From Harrow, Inc.
    Via Business Wire
    Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025
    From Harrow, Inc.
    Via Business Wire
    Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
    From Harrow, Inc.
    Via Business Wire
    Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
    From Harrow, Inc.
    Via Business Wire
    Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
    From Harrow, Inc.
    Via Business Wire
    Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
    From Melt Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.